Evidence map›Paper›PMID 25853061›Full record

ArticleMeta gene2015

KIR genotype distribution among Lebanese patients with Hodgkin's lymphoma.

Rouba Hoteit, Miguel Abboud, Ali Bazarbachi, Ziad Salem, Dina Shammaa, Ghazi Zaatari, Rami Mahfouz

Open access · hybridAbstract read
In one paragraph

Article in Meta gene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rouba HoteitDepartment of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon.
Miguel AbboudDepartment of Pediatrics, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon.
Ali BazarbachiDepartment of Internal Medicine, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon.
Ziad SalemDepartment of Internal Medicine, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon.
Dina ShammaaDepartment of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon.
Ghazi ZaatariDepartment of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon.
Rami MahfouzDepartment of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut 1107-2020, Lebanon.
American University of Beirut Medical Center · LB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn addition to their important role in fighting infection, natural killer cells are cytotoxic to cancer cells. Studies demonstrated that some KIR genes were responsible for the reduction of the risk of Hodgkin's lymphoma (HL) while others were associated with an increased risk of HL.

aimThe aim of this study is to assess KIR genotypic distribution in Lebanese patients with Hodgkin's lymphoma.

methodsKIR genotype was analyzed in 41 HL patients and 120 healthy Lebanese individuals using the KIR Genotyping SSP kit.

resultsNo significant association between HL and any KIR gene was found. Among HL patients, the AA, AB, and BB genotype frequencies were, respectively, 41.46%, 43.9% and 14.63% with an A:B ratio of 1.73:1. As for the controls, the AA, AB, and BB genotype frequencies were, respectively, 39.17%, 50%, and 10.83% with an A:B ratio of 1.79:1.

conclusionIn this first study from the Mediterranean region, KIR genotype does not seem to be associated with Hodgkin's lymphoma. Further clinical and translational research is needed to rule out the protective or predisposing role of KIR genes in this important clinical entity.

Indexed as

DNA, Deoxyribonucleic acidGenotypeHLA, Human Leukocyte AntigensHL, Hodgkin’s LymphomaHodgkin'sIRB, Institutional Review BoardKIRKIR, Killer Cell Immunoglobulin-like ReceptorsLebanonLPHL, Lymphocyte predominant Hodgkin’s lymphomaLRC, leukocyte Receptor ComplexLymphomaMHC, Major Histocompatibility ComplexNK, Natural killerPCR, Polymerase Chain ReactionSSP, Sequence Specific PrimersUV, Ultraviolet

Identifiers

PMID25853061
PMCPMC4381114
OpenAlexW2012018564

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.